Re-examination of MAGE-A3 as a T-cell Therapeutic Target-Reference-Cited by-同舟云学术

Re-examination of MAGE-A3 as a T-cell Therapeutic Target

Published:2020-12-04 Issue:3 Volume:44 Page:95-105
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Martin Aaron D.,Wang Xueyin,Sandberg Mark L.,Negri Kathleen R.,Wu Ming L.,Toledo Warshaviak Dora,Gabrelow Grant B.,McElvain Michele E.,Lee Bella,Daris Mark E.,Xu Han,Kamb Alexander

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference31 articles.

1. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells;Cameron;Sci Transl Med,2013

2. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy;Morgan;J Immunother,2013

3. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions;Robbins;J Immunol,2008

4. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells;Parkhurst;Clin Cancer Res,2009

5. High-affinity TCRs generated by phage display provide CD4 + T cells with the ability to recognize and kill tumor cell lines;Zhao;J Immunol,2007

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The physiological interactome of TCR-like antibody therapeutics in human tissues;Nature Communications;2024-04-16

2. Adoptive T cell therapy for solid tumors: current landscape and future challenges;Frontiers in Immunology;2024-03-14

3. The role of CD4⁺ T cells in tumor and chronic viral immune responses;MedComm;2023-10

4. MAGE-A10 Protein Expression in Advanced High Grade Serous Ovarian Cancer Is Associated with Resistance to First-Line Platinum-Based Chemotherapy;Cancers;2023-09-23

5. Multi-tiered approach to detect autoimmune cross-reactivity of therapeutic T cell receptors;Science Advances;2023-07-28